Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Corbus Pharmaceuticals Holding (CRBP)

NASDAQ
Currency in USD
Disclaimer
39.2400
+3.6700(+10.32%)
Closed
After Hours
39.8100+0.5700(+1.4526%)
Fair Value
Unlock Value
Day's Range
35.163639.9600
52 wk Range
3.033449.8699
Prev. Close
35.57
Open
35.42
Day's Range
35.1636-39.96
52 wk Range
3.0334-49.8699
Volume
234,817
Average Volume (3m)
925,407
1-Year Change
387.45%
Shares Outstanding
10,507,237
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
55.0000
Upside +40.1631%

People Also Watch

1,010.03
SMCI
-1.30%
124.99
ARM
-0.50%
87.88
CVNA
-2.69%
5.89
SOUN
-0.67%
1,704.56
MSTR
-11.18%
How do you feel today about CRBP?
Vote to see community's results!
or

Corbus Pharmaceuticals Holding Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company. The Company is engaged in developing and commercializing therapeutics for autoimmunity, fibrosis, and cancer. Its internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. It has developed CRB-913, a second-generation cannabinoid receptor type 1 (CB1) inverse agonist designed to treat obesity and related metabolic diseases. The CRB-913 program is in the pre-clinical-stage. It also includes Lenabasum, which is a novel, synthetic, oral molecule that selectively activates cannabinoid receptor type 2 (CB2) for the treatment of inflammation and fibrosis. Its subsidiaries include Corbus Pharmaceuticals, Inc., Corbus International Limited and Corbus Pharmaceuticals Australia Pty Ltd.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.